Transthyretin Amyloidosis—One of the Causes of Heart Failure in Patients with Severe Clinical Course of COVID-19
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26199806 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Zarina Gioeva und 8 weiteren Autor:innen. Beteiligte Einrichtung: Avtsyn Research Institute of Human Morphology of Federal State Budgetary Scientific Institution, "Petrovsky National Research Centre of Surgery", 117…. Hauptthemen laut MEDLINE: COVID-19, Heart Failure, Amyloid Neuropathies, Familial. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation, Ministry of Education and Science of the Russian Federation.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Wild-type transthyretin amyloidosis is an underdiagnosed condition that significantly contributes to mortality in the elderly population. This histopathological study describes autopsy findings in patients with severe clinical course of COVID-19 and ATTR not identified during life. Autopsy findings in the myocardium were analyzed in 19 patients with pre-existing ATTR who died from severe COVID-19. RT PCR was used for pre- and post-mortem detection of SARS-CoV-2 RNA. Immunohistochemical typing was performed with a broad panel of antibodies against different amyloid types. Autopsy specimens from the myocardium and lungs were positive for SARS-CoV-2 RNA in 10 (53%) cases. Microscopic examination of the myocardium revealed focal cardiosclerosis and cardiomyocyte dissociation in 15 (68%) cases, hypertrophy and atrophy of cardiomyocytes in 17 (77%) and 7 (32%), respectively, and myocarditis in 4 (18%) cases. Immunohistochemical analysis determined ATTR amyloidosis in all cases. In patients with rapidly progressive heart failure, the postmortem examination revealed multiple sites of interstitial amyloid deposits and focal cardiosclerosis in the myocardium. Pre-existing cardiac amyloidosis contributes to the aggressive clinical course of COVID-19. Coupled with the toxic effect of the SARS-CoV-2 virus on the myocardium, the disease may lead to progressive heart failure and poor outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Avtsyn Research Institute of Human Morphology of Federal State Budgetary Scientific Institution, "Petrovsky National Research Centre of Surgery", 117418 Moscow, Russia.
- Institute of Medicine, Peoples' Friendship University of Russia, 117198 Moscow, Russia.
ORCID-Profile: Zarina Gioeva, Liudmila Mikhaleva, Nikita Gutyrchik, Nikolay Shakhpazyan, Valentina Pechnikova, Konstantin Midiber, Lev Kakturskij
Förderung
- Russian Science Foundation
- Ministry of Education and Science of the Russian Federation
Zitieren
APA
Gioeva, Z., Mikhaleva, L., Gutyrchik, N., Shakhpazyan, N., Pechnikova, V., Midiber, K., Kontorshchikov, A., Zentsova, E., & Kakturskij, L. (2025). Transthyretin Amyloidosis—One of the Causes of Heart Failure in Patients with Severe Clinical Course of COVID-19. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199806
Vancouver
Gioeva Z, Mikhaleva L, Gutyrchik N, Shakhpazyan N, Pechnikova V, Midiber K, et al. Transthyretin Amyloidosis—One of the Causes of Heart Failure in Patients with Severe Clinical Course of COVID-19. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199806
BibTeX
@article{Gioeva2025,
author = {Gioeva, Zarina and Mikhaleva, Liudmila and Gutyrchik, Nikita and Shakhpazyan, Nikolay and Pechnikova, Valentina and Midiber, Konstantin and Kontorshchikov, Andrej and Zentsova, Elizaveta and Kakturskij, Lev},
title = {Transthyretin Amyloidosis—One of the Causes of Heart Failure in Patients with Severe Clinical Course of COVID-19},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26199806}
}
EUVIMED